Novartis AG
NEW PROCESS FOR EARLY SACUBITRIL INTERMEDIATES

Abstract:

The invention relates to a new enantioselective process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a .gamma.-amino-.delta.-biphenyl-.alpha.-methylalkanoic acid, or acid ester, backbone.